Abstract
The B&D Committee membership includes all participating international study groups. It provides a bridge between the other I-BFM Committees in terms of integration of technical developments, collaborative studies to determine the clinical and prognostic relevance of novel genetic abnormalities in childhood leukaemia and lymphoma. This Committee is most closely aligned with the Genetic Variation, Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia and Resistant Disease Committees, with which joint and overlapping meetings are carried out. There has been major focus over the years on studies of minimal residual disease (MRD) and validation of new technologies for their integration into clinical practice.
Scientific aims
- to validate the clinical and prognostic relevance of new genetic subtypes of childhood leukaemia and lymphoma
- to explore the relevance of biological factors in these diseases
- to explore biological studies in relation to improving therapies for these diseases
- to validate emerging new technologies in the field for clinical application
B&D Committee ongoing collaborative studies:
IGH translocation partners (coordinated by L. Russell)
Down syndrome ALL Registry (coordinated by M. Den Boer and S. Izraeli)
ETV6::RUNX1-like ALL (coordinated by M.Zaliova)
NUTM1 and other non-MLL Infant-ALL (coordinated by G. Cazzaniga and J. Boer)
TP53 in hypodiploid ALL (coordinated by G. Cazzaniga)
Harmony (coordinated by A. Moorman)
Consensus diagnostic approaches for clinically actionable genetic abnormalities in ALL (coordinated by C. Harrison)
Selected collaborative publications of the BD members
IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.
Stanulla M, Dagdan E, Zaliova M, Möricke A, Palmi C, Cazzaniga G, Eckert C, Te Kronnie G, Bourquin JP, Bornhauser B, Koehler R, Bartram CR, Ludwig WD, Bleckmann K, Groeneveld-Krentz S, Schewe D, Junk SV, Hinze L, Klein N, Kratz CP, Biondi A, Borkhardt A, Kulozik A, Muckenthaler MU, Basso G, Valsecchi MG, Izraeli S, Petersen BS, Franke A, Dörge P, Steinemann D, Haas OA, Panzer-Grümayer R, Cavé H, Houlston RS, Cario G, Schrappe M, Zimmermann M; TRANSCALL Consortium; International BFM Study Group. J Clin Oncol. 2018 Apr 20;36(12):1240-1249.
International cooperative study identifies treatment strategy in childhood
ambiguous lineage leukemia
Hrusak O, De Haas V, Stancikova J, Vakrmanova B, Janotova I, Mejstrikova E, Capek V, Trka J, Zaliova M, Luka V, Bleckmann K, Möricke A, Irving J, Konatkowska B, Alexander TB, Inaba H, Schmiegelow K, Stokley S, Zemanova Z, Moorman AV, Rossi AG, Felice MS, Dalla-Pozza L, Morales J, Dworzak M, Buldini B, Basso G, Campbell M, Cabrera ME, Marinov N, Elitzur S, Izraeli S, Luria D, Feuerstein T, Kolenova A, Svec P, Kreminska O, Rabin KR, Polychronopoulou S, da Costa E, Marquart HV, Kattamis A, Ratei R, Reinhardt D, Choi JK, Schrappe M, Stary J. Blood (in press)
Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?
Schwab C, Nebral K, Chilton L, Leschi C, Waanders E, Boer JM, Žaliová M, Sutton R, Öfverholm II, Ohki K, Yamashita Y, Groeneveld-Krentz S, Froňková E, Bakkus M, Tchinda J, Barbosa TDC, Fazio G, Mlynarski W, Pastorczak A, Cazzaniga G, Pombo-de-Oliveira MS, Trka J, Kirschner-Schwabe R, Imamura T, Barbany G, Stanulla M, Attarbaschi A, Panzer-Grümayer R, Kuiper RP, den Boer ML, Cavé H, Moorman AV, Harrison CJ, Strehl S. on behalf of International BFM Study Group. Blood Adv. 2017 Aug 14;1(19):1473-1477.
The MLL recombinome of acute leukemias in 2017.
Meyer C, Burmeister T, Gröger D, Tsaur G, Fechina L, Renneville A, Sutton R, Venn NC, Emerenciano M, Pombo-de-Oliveira MS, Barbieri Blunck C, Almeida Lopes B, Zuna J, Trka J, Ballerini P, Lapillonne H, De Braekeleer M, Cazzaniga G, Corral Abascal L, van der Velden VHJ, Delabesse E, Park TS, Oh SH, Silva MLM, Lund-Aho T, Juvonen V, Moore AS, Heidenreich O, Vormoor J, Zerkalenkova E, Olshanskaya Y, Bueno C, Menendez P, Teigler-Schlegel A, Zur Stadt U, Lentes J, Göhring G, Kustanovich A, Aleinikova O, Schäfer BW, Kubetzko S, Madsen HO, Gruhn B, Duarte X, Gameiro P, Lippert E, Bidet A, Cayuela JM, Clappier E, Alonso CN, Zwaan CM, van den Heuvel-Eibrink MM, Izraeli S, Trakhtenbrot L, Archer P, Hancock J, Möricke A, Alten J, Schrappe M, Stanulla M, Strehl S, Attarbaschi A, Dworzak M, Haas OA, Panzer-Grümayer R, Sedék L, Szczepański T, Caye A, Suarez L, Cavé H, Marschalek R. Leukemia. 2018 Feb;32(2):273-284
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G, De Lorenzo P, Alten J, Röttgers S, Hancock J, Saha V, Castor A, Madsen HO, Gandemer V, Cavé H, Leoni V, Köhler R, Ferrari GM, Bleckmann K, Pieters R, van der Velden V, Stary J, Zuna J, Escherich G, Stadt UZ, Aricò M, Conter V, Schrappe M, Valsecchi MG, Biondi A. Haematologica. 2018 Jan;103(1):107-115.
High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia.
Vendramini E, Giordan M, Giarin E, Michielotto B, Fazio G, Cazzaniga G, Biondi A, Silvestri D, Valsecchi MG, Muckenthaler MU, Kulozik AE, Gattei V, Izraeli S, Basso G, Te Kronnie G.
Oncotarget. 2017 Jun 27;8(26):42398-42413.
Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
Schwartzman O, Savino AM, Gombert M, Palmi C, Cario G, Schrappe M, Eckert C, von Stackelberg A, Huang JY, Hameiri-Grossman M, Avigad S, Te Kronnie G, Geron I, Birger Y, Rein A, Zarfati G, Fischer U, Mukamel Z, Stanulla M, Biondi A, Cazzaniga G, Vetere A, Wagner BK, Chen Z, Chen SJ, Tanay A, Borkhardt A, Izraeli S.
Proc Natl Acad Sci U S A. 2017 May 16;114(20):E4030-E4039.
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease Jan Zuna, Lenka Hovorkova, Justina Krotka, Amelie Koehrmann, Michela Bardini, Lucie Winkowska, Eva Fronkova , Julia Alten, Rolf Koehler, Cornelia Eckert, Lisa Brizzolara, Marie Trkova, Jan Stuchly , Martin Zimmermann, Paola De Lorenzo, Maria Grazia Valsecchi, Valentino Conter, Jan Stary, Martin Schrappe, Andrea Biondi, Jan Trka, Marketa Zaliova, Giovanni Cazzaniga, Gunnar Cario (2022)
Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group. Ohki, K., Butler, E.R., Kiyokawa, N., Hirabayashi, S., Bergmann, A.K., Möricke, A., Boer, J.M., Cavé, H., Cazzaniga, G., Yeoh, A.E.J., Sanada, M., Imamura, T., Inaba, H., Mullighan, C.G., Loh, M.L., Norén-Nyström, U., Shih, L-Y., Zaliova, M., Pui, C-H., Haas, O.A., Harrison, C.J., Moorman, A.V., Manabe, A. (2023) Leukemia (in press)
Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: A retrospective analysis by the Ponte di Legno Childhood ALL Working Group. Hirabayashi, S., Butler, E., Ohki, K., Kiyokawa, N., Bergmann, A., Moericke, A., Boer, J., Cavé, H., Cazzaniga, G., Yeoh, A., Sanada, M., Imamura, T., Inaba, H., Mullighan, C., Loh, M., Norén-Nyström, U., Pastorczak, A., Shih, L-H., Zaliova, M., Pui, C-H., Haas, O., Harrison, C.J., Moorman, A.V., Manabe, A. (2021) Leukemia 35(11):3272-3277
